8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A detailed review of MOTS-c regulatory status in the United States, including FDA approval history, compounding legality, labeling requirements, and current safety data as of 2025.
A detailed comparison of how the FDA and EMA approach MOTS-c, covering regulatory classification, label status, safety data, and clinical evidence as of 2025.
MOTS-c has no FDA approval, no FAERS profile, and no official drug label. Here is what the regulatory landscape looks like for this mitochondrial-derived peptide and what safety data actually exists.
A complete review of MOTS-c regulatory status with the FDA, available safety data, compounding and research-use context, and what the current label (or absence of one) means for clinicians and patients.
MOTS-c has no FDA approval and remains an investigational mitochondrial peptide worldwide. Learn its regulatory classification in the US, EU, Australia, and Asia, plus the clinical evidence behind ongoing research.
MOTS-c has no FDA approval and no drug label. This article covers the full regulatory timeline from 2020 to 2026, including FDA peptide enforcement actions, research milestones, and safety data for this mitochondrial-derived peptide.
MOTS-c remains unapproved by the FDA with no IND-stage clinical trials in humans. This article covers the patent disputes, regulatory classification questions, and safety concerns surrounding this mitochondrial-derived peptide.
MOTS-c has no FDA approval and remains an investigational mitochondrial-derived peptide. Review the preclinical pipeline, safety signals, regulatory outlook, and what published research actually shows about this novel metabolic peptide.